

# Markers of interferon signaling and glutamine utilization within the stromal microenvironment in Head & Neck Squamous Cell Carcinoma (HNSCC) predict cancer recurrence

Raymond Yan<sup>1</sup>, Brian Falkenstein<sup>1</sup>, A. Burak Tosun<sup>1</sup>, James Monkman<sup>2</sup>, Filippo Pullara<sup>1</sup>, Arutha Kulasinghe<sup>2</sup>, S Chakra Chennubhotla<sup>1,3</sup>

<sup>1</sup>PredxBio, Inc., 100 S. Jackson Ave., Pittsburgh, PA USA 15202; <sup>2</sup>Frazer Institute, Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia; <sup>3</sup>Dept. of Computational and Systems Biology, University of Pittsburgh, Pittsburgh, USA

## Background

- Intra- and inter-tumor heterogeneity in head and neck cancers can lead to phenotypic diversity that makes cancer prognosis difficult to assess accurately.
- The heterogeneity that lies within the tumor-stroma interactions are poorly understood.
- There is an unmet clinical need to develop phenotypic signatures that can be predictive of clinical progression and therapeutic outcomes.

## Methods

- In this study, we applied our SpaceIQ™ platform to identify a subset of key markers characteristic of the complex tumor microenvironment features that can be used to derive a predictive test for a patient's likelihood of cancer recurrence.
- We applied cell segmentation and unbiased cell typing on spatial proteomics data (43 cores of 67-plex mIF panel across 15 pre-treated patients with 5 non-recurrence status) yielding 23 cell types.
- Recurrence-specific microdomains, which are spatial arrangements of cells that are differentially expressed between the two response groups, were derived from pointwise mutual information between the unbiased cell types.
- Further, a de-plexing algorithm was implemented to obtain a low-dimensional proxy representation for each of the unbiased cell types involved in the microdomains based on their biomarker profiles.
- Finally, a prognostic modeling strategy, based on de-plexed representation, employing a spatial score between cell types and an estimated mean biomarker expression as predictive features to the recurrence outcome.

## Results

- We identified several spatial interactions associated with non-recurrence:
  - spatial interaction between M2 macrophages (unbiased cell type 21111) with anti-inflammatory Tregs (unbiased cell type 22200) was predictive of recurrence outcome AUC=0.73 (0.71,0.74)
  - spatial interaction between regulatory T cells (unbiased cell type 12121) with IFNG-activated, glutamine-dependent (ASCT1) mature NK cells (unbiased cell type 12212) was predictive of recurrence outcome with AUC=0.80 (0.79,0.81)
  - spatial interaction between iNOS-mediated regulatory T cells (unbiased cell type 12220) with epithelial cells of Microdomain 3 was predictive of recurrence outcome with AUC=0.75 (0.74,0.76)


## Conclusions

- We uncovered key spatial signatures of tumor non-recurrence in HNSCC patients involving interactions between M2 macrophages and Tregs, stromal immune cells, and mature NK cells.
- These spatial interactions demonstrate the complexity of the TME affected by Wnt/b-Catenin signaling regulation on ECM remodeling, fibrotic processes, and iNOS-mediated immune regulation, in addition to potential glutamine-dependent facilitation of epithelial tumor invasion by IFNG mature NK cells.
- Through the SpaceIQ platform, we were able to de-plex a 67-plex IF panel to a few key predictive biomarkers involving macrophages, Tregs, and glutamine-dependent NK cells yielding good predictive performance for recurrence outcome in HNSCC patients.

## Discriminatory Markers for Biological Interpretation of Unbiased Recursive Cell Types

Cell Type (%)	Inverse Coefficient of Variation ( $\mu/\sigma$ )	Discriminatory Biomarkers
HN- 11110 (3.6%)	-	CPT1A-
HN- 11121 (3.8%)	-	CPT1A-
HN- 11122 (0.4%)	-	CPT1A-
HN- 11211 (2.3%)	-	CPT1A- CPT1A-/G6PD-
HN- 11212 (3.6%)	-	CPT1A-
HN- 11220 (28.8%)	-	CPT1A-
HN- 12110 (1.3%)	-	CPT1A-
HN- 12121 (0.6%)	-	CPT1A-
HN- 12122 (0.3%)	-	CPT1A-
HN- 12211 (0.3%)	-	CPT1A-
HN- 12212 (1.2%)	-	CPT1A-
HN- 12220 (1.8%)	-	CPT1A-
HN- 21111 (8.1%)	-	ASCT2-
HN- 21112 (11.3%)	-	pNRFR2+/CS+/CPT1A+/ASCT2+/G6PD+
HN- 21121 (8.3%)	-	CS+
HN- 21122 (0.6%)	-	CS+
HN- 21211 (3.7%)	-	CS+/CPT1A+
HN- 21220 (3.0%)	-	pNRFR2+/CS+/CPT1A+/ASCT2+
HN- 22110 (2.8%)	-	pNRFR2+/CS+
HN- 22121 (3.2%)	-	CS+
HN- 22122 (1.6%)	-	CPT1A-/ASCT2-
HN- 22200 (9.0%)	-	CPT1A-/ASCT2-
GLUT1- pNRFR2- CS- CPT1A- ASCT2- G6PD-	2	


## Cellular Heterogeneity Visualized



## References


[1] Monkman et al Immunology, 2023; [2] Uttam, S, et al Nat. Comm., 2020; [3] Furman SA, Cell. Rep. Met., 2021; [4] Spagnolo D et al, JPI, 2016

## Unbiased Cell Typing Extracts Numerically Stable, Spatially Distinct and Biologically Interpretable Recursive Cell Types




- Dynamic range of cell mean intensity distribution on 67 markers colored by marker type that were used for unbiased cell typing.
- Recursive hierarchical tree at each level bi-partitioning of parent node cell population into children nodes. The root node represents all nonepithelial cells undergoing unbiased cell typing. Brown nodes denote distinct clusters at a given level based on a positive estimated Silhouette score. Red leaf nodes denote descendants that have a distinct ancestral node beyond the first level split. Purple leaf nodes denote descendants that do not have a distinct ancestral node beyond the first level split.
- Estimated inverse coefficient of variation of the z-scores for each marker for each of the cell population clusters from the first level split of unbiased cell typing.
- Recurrence and non-recurrence cores showing the cells from the first level split. Cells in gray are the epithelial cells.

## μDs Emerge as Spatial Networks of Immuno-Metabolic Cell Types



## Microdomains are Spatially Distinct IFNG and iNOS Modulated Immuno-Regulatory Programs that Predict ICI Response



## Contact:

- Chakra Chennubhotla, PhD  
[chakra@predxbio.com](mailto:chakra@predxbio.com)  
[chakracs@pitt.edu](mailto:chakracs@pitt.edu)
- Arutha Kulasinghe, PhD  
[arutha.kulasinghe@uq.edu.au](mailto:arutha.kulasinghe@uq.edu.au)

